Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia

被引:1
作者
Ansstas, George [1 ]
Vij, Ravi [1 ]
机构
[1] Washington Univ, Sch Med, Sect Bone Marrow Transplant & Leukemia, St Louis, MO 63110 USA
关键词
Chronic myeloid leukemia; chronic myelogenous leukemia; progression-free survival; event-free survival; disease progression; BCR-ABL inhibitor; DIAGNOSED CHRONIC-PHASE; COMPLETE CYTOGENETIC RESPONSE; CHRONIC MYELOGENOUS LEUKEMIA; KINASE INHIBITOR THERAPY; ALPHA PLUS CYTARABINE; MOLECULAR RESPONSES; FOLLOW-UP; IMATINIB; INTERFERON; DASATINIB;
D O I
10.3109/10428194.2011.653786
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Standardized definitions of response and outcome are useful to evaluate study data, facilitate treatment guideline adherence and aid clinical decision-making. Although definitions of response in chronic myeloid leukemia (CML) have been standardized, definitions of disease progression have not been standardized, despite widespread adoption of the term to reflect development of advanced disease. This article reviews definitions of response and disease progression used for progression-free survival and event-free survival in key CML studies and implications for interpreting patient response. It is proposed that adherence to definitions of progression from the European LeukmiaNet may aid future research and therapeutic decision-making.
引用
收藏
页码:1273 / 1281
页数:9
相关论文
共 39 条
[1]   Current Event-Free Survival After Sequential Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia [J].
Al-Kali, Aref ;
Kantarjian, Hagop ;
Shan, Jianqin ;
Bassett, Roland ;
Quintas-Cardama, Alfonso ;
Borthakur, Gautam ;
Jabbour, Elias ;
Verstovsek, Srdan ;
O'Brien, Susan ;
Cortes, Jorge .
CANCER, 2011, 117 (02) :327-335
[2]  
[Anonymous], NCCN CLIN PRACT GUID
[3]   Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].
Baccarani, Michele ;
Saglio, Giuseppe ;
Goldman, John ;
Hochhaus, Andreas ;
Simonsson, Bengt ;
Appelbaum, Frederick ;
Apperley, Jane ;
Cervantes, Francisco ;
Cortes, Jorge ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Frangois ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Niederwieser, Dielger ;
Silver, Richard ;
Hehlmann, Rudiger .
BLOOD, 2006, 108 (06) :1809-1820
[4]   Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].
Baccarani, Michele ;
Cortes, Jorge ;
Pane, Fabrizio ;
Niederwieser, Dietger ;
Saglio, Giuseppe ;
Apperley, Jane ;
Cervantes, Francisco ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Francois ;
Hochhaus, Andreas ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Radich, Jerald ;
Simonsson, Bengt ;
Silver, Richard T. ;
Goldman, John ;
Hehlmann, Rudiger .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051
[5]   Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study [J].
Baccarani, Michele ;
Rosti, Gianantonio ;
Castagnetti, Fausto ;
Haznedaroglu, Ibrahim ;
Porkka, Kimmo ;
Abruzzese, Elisabetta ;
Alimena, Giuliana ;
Ehrencrona, Hans ;
Hjorth-Hansen, Henrik ;
Kairisto, Veli ;
Levato, Luciano ;
Martinelli, Giovanni ;
Nagler, Arnon ;
Nielsen, Johan Lanng ;
Ozbek, Ugur ;
Palandri, Francesca ;
Palmieri, Fausto ;
Pane, Fabrizio ;
Rege-Cambrin, Giovanna ;
Russo, Domenico ;
Specchia, Giorgina ;
Testoni, Nicoletta ;
Weiss-Bjerrum, Ole ;
Saglio, Giuseppe ;
Simonsson, Bengt .
BLOOD, 2009, 113 (19) :4497-4504
[6]   Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials [J].
Branford, Susan ;
Fletcher, Linda ;
Cross, Nicholas C. P. ;
Mueller, Martin C. ;
Hochhaus, Andreas ;
Kim, Dong-Wook ;
Radich, Jerald P. ;
Saglio, Giuseppe ;
Pane, Fabrizio ;
Kamel-Reid, Suzanne ;
Wang, Y. Lynn ;
Press, Richard D. ;
Lynch, Kevin ;
Rudzki, Zbigniew ;
Goldman, John M. ;
Hughes, Timothy .
BLOOD, 2008, 112 (08) :3330-3338
[7]   Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase [J].
Cortes, Jorge E. ;
Jones, Dan ;
O'Brien, Susan ;
Jabbour, Elias ;
Konopleva, Marina ;
Ferrajoli, Alessandra ;
Kadia, Tapan ;
Borthakur, Gautam ;
Stigliano, Denise ;
Shan, Jianqin ;
Kantarjian, Hagop .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :392-397
[8]   Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia [J].
Cortes, Jorge E. ;
Jones, Dan ;
O'Brien, Susan ;
Jabbour, Elias ;
Ravandi, Farhad ;
Koller, Charles ;
Borthakur, Gautam ;
Walker, Brenda ;
Zhao, Weiqiang ;
Shan, Jianqin ;
Kantarjian, Hagop .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :398-404
[9]   Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission [J].
Craddock, C ;
Szydio, RM ;
Klein, JP ;
Dazzi, F ;
Olavarria, E ;
van Rhee, F ;
Pocock, C ;
Cwynarski, K ;
Apperley, JF ;
Goldman, JM .
BLOOD, 2000, 96 (01) :86-90
[10]   Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis [J].
de Lavallade, Hugues ;
Apperley, Jane F. ;
Khorashad, Jamshid S. ;
Milojkovic, Dragana ;
Reid, Alistair G. ;
Bua, Marco ;
Szydlo, Richard ;
Olavarria, Eduardo ;
Kaeda, Jaspal ;
Goldman, John M. ;
Marin, David .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3358-3363